UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Grant Review Feedback: Appropriateness and Usefulness

Science and engineering ethics, 2021-04, Vol.27 (2), p.18-18, Article 18

2021

Link zum Volltext

Verfügbarkeit prüfen

The Participation and Motivations of Grant Peer Reviewers: A Comprehensive Survey

Science and engineering ethics, 2020-04, Vol.26 (2), p.761-782

2020

Link zum Volltext

Verfügbarkeit prüfen

Grant reviewer perceptions of the quality, effectiveness, and influence of panel discussion

Research integrity and peer review, 2020-05, Vol.5 (1), p.7-7, Article 7

2020

Link zum Volltext

Verfügbarkeit prüfen

Do funding applications where peer reviewers disagree have higher citations? A cross-sectional study. [version 2; peer review: 2 approved]

F1000 research, 2018, Vol.7, p.1030-1030

2018

Link zum Volltext

Verfügbarkeit prüfen

External Tests of Peer Review Validity Via Impact Measures

Frontiers in research metrics and analytics, 2018-08, Vol.3

2018

Link zum Volltext

Verfügbarkeit prüfen

Peer Review: A System under Stress

Bioscience, 2017-05, Vol.67 (5), p.407-410

2017

Link zum Volltext

Verfügbarkeit prüfen

Risk evaluation in peer review of grant applications

Environment systems & decisions, 2018-06, Vol.38 (2), p.216-229

2018

Link zum Volltext

Verfügbarkeit prüfen

The Role of Fatigue in Susceptibility to Acute Muscle Strain Injury

The American journal of sports medicine, 1996-03, Vol.24 (2), p.137-143

1996

Link zum Volltext

Verfügbarkeit prüfen

Image Segmentation Stability: An Empirical Investigation

SoutheastCon 2018, 2018, p.1-8

2018

Link zum Volltext
Volltext

ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology

Journal of thoracic oncology, 2016-11, Vol.11 (11), p.S252-S253

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer

Journal of clinical oncology, 2002-01, Vol.20 (2), p.364-370

Shin, D. M.

2002

Link zum Volltext

Verfügbarkeit prüfen

ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC

Journal of thoracic oncology, 2016-11, Vol.11 (11), p.S252-S253

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC)

Journal of clinical oncology, 2016-06, Vol.34 (18_suppl), p.LBA8505-LBA8505

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.LBA8505-LBA8505

2016

Link zum Volltext

Verfügbarkeit prüfen

OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S260-S261

2017

Link zum Volltext

Verfügbarkeit prüfen

Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3608-3608

2015

Link zum Volltext

Verfügbarkeit prüfen

Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway

JNCI : Journal of the National Cancer Institute, 2013-10, Vol.105 (20), p.1558-1570

2013

Link zum Volltext

Verfügbarkeit prüfen

Combating Resistance to Anti-IGFR Antibody by Targeting the Intergrin [Beta]3-Src Pathway

JNCI : Journal of the National Cancer Institute, 2013-10, Vol.105 (20), p.1558

2013

Link zum Volltext

Verfügbarkeit prüfen

Akt/mammalian target of rapamycin counteract the antitumor activities of cixutumumab an anti-insulin-like growth factor I receptor monoclonal antibody

Molecular cancer therapeutics, 2011-10, Vol.10 (12), p.2437-2448

2011

Link zum Volltext

Verfügbarkeit prüfen

Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.5592-5592

2012

Link zum Volltext

Verfügbarkeit prüfen

Investigation of PARP1 as a therapeutic target in small cell lung cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7096-7096

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1901: EGFR and K-Ras mutations and resistance of lung cancers to IGF-1R TKI

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1901-1901

2012

Link zum Volltext

Verfügbarkeit prüfen

EGFR and K-Ras Mutations and Resistance of Lung Cancer to IGF-1R Tyrosine Kinase Inhibitors

Cancer, 2012-02, Vol.118 (16), p.3993-4003

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4127: EGFR and K-Ras mutations and resistance of lung cancer to the IGF-1R tyrosine kinase inhibitors

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4127-4127

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(27)
Tagungsberichte
(1)

Sprache

Englisch
(28)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(7)
Peer Review
(6)
Research Funding
(5)
Life Sciences & Biomedicine
(4)
Arts & Humanities
(3)
Engineering
(3)
Ethics
(3)
Funding
(3)
Grant Applications
(3)
History & Philosophy Of Science
(3)
Social Sciences
(3)
Social Sciences - Other Topics
(3)
Technology
(3)
Bias
(2)
Bioethics
(2)
Biomedical Engineering And Bioengineering
(2)
Biowissenschaft
(2)
Education
(2)
Engineering, Multidisciplinary
(2)
Innovation
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Grant Review Feedback: Appropriateness and Usefulness

The Participation and Motivations of Grant Peer Reviewers: A Comprehensive Survey

Grant reviewer perceptions of the quality, effectiveness, and influence of panel discussion

Do funding applications where peer reviewers disagree have higher citations? A cross-sectional study. [version 2; peer review: 2 approved]

External Tests of Peer Review Validity Via Impact Measures

Peer Review: A System under Stress

Risk evaluation in peer review of grant applications

The Role of Fatigue in Susceptibility to Acute Muscle Strain Injury

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

Image Segmentation Stability: An Empirical Investigation

ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology

Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer

ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC)

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC)

OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)

Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment

Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway

Combating Resistance to Anti-IGFR Antibody by Targeting the Intergrin [Beta]3-Src Pathway

Akt/mammalian target of rapamycin counteract the antitumor activities of cixutumumab an anti-insulin-like growth factor I receptor monoclonal antibody

Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN)

Investigation of PARP1 as a therapeutic target in small cell lung cancer

Abstract 1901: EGFR and K-Ras mutations and resistance of lung cancers to IGF-1R TKI

EGFR and K-Ras Mutations and Resistance of Lung Cancer to IGF-1R Tyrosine Kinase Inhibitors

Abstract 4127: EGFR and K-Ras mutations and resistance of lung cancer to the IGF-1R tyrosine kinase inhibitors

Aktive Filter

Suchergebnisse filtern